Work Area: Transactions

Latest content

Report questions high published royalty rates for voice codec SEPs

Analysis from Stout suggests rates sought by certain Enhanced Voice Services (EVS) patent owners are out of line with the overall 3G/4G/5G FRAND landscape

18 May 2022

Patents peripheral to Twitter’s success, but know-how absolutely crucial

Elon Musk will have to make certain that IP vital to the company’s future cannot just walk out the door

06 May 2022

Michael Vladescu RIP

WiLAN boss’s untimely death announced by firm’s parent company Quarterhill

05 May 2022

Oppo acquires wireless, video coding patents from Sharp

Chinese handset vendor taps portfolio of former litigation opponent as disputes with Nokia and InterDigital heat up

05 May 2022

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

04 May 2022

Vidal confirmation calms market outlook on Biden patent policy

Featured in Community Insight

After getting a chance to hear from the US president’s pick to lead the USPTO, respondents to IAM’s insight panel swung from negative to neutral

02 May 2022

IP transactions in life sciences in ASEAN countries: data exclusivity

While the respective IP laws of ASEAN states differ with regard to data exclusivity in the field of life sciences, all are focused on strengthening the enforcement of IP rights for pharmaceutical products.

27 April 2022

IP transactions in life sciences in ASEAN countries: IP ownership and sharing

The respective IP laws of ASEAN states differ when it comes to IP ownership and sharing provisions.

20 April 2022

Samsung Electronics transfers patents to monetisation business run by former in-house counsel

Entity assigned more than 100 patents by the Korean tech giant is run by previous chief of Samsung’s semiconductor IP division

19 April 2022

$1.9 billion transaction is another boost for non-core IP deal-making in pharma

Sierra Oncology buyout is motivated by previously unwanted drug asset it bought for a $3 million upfront fee

15 April 2022

Get unlimited access to all IAM content